December 3, 2016 06:28 PM ESTUpdated May 26, 08:50 PM
Cell/Gene Tx

Spark’s de­liv­ery vec­tor trig­gers an­oth­er trou­bling im­mune re­ac­tion, but R&D team main­tains he­mo­phil­ia B ef­fi­ca­cy

John Carroll

Editor & Founder

One month af­ter Spark Ther­a­peu­tics $ONCE spooked its in­vestors with the news of one im­mune re­ac­tion to its gene ther­a­py in a small he­mo­phil­ia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times